Introduction. In assessing erythropoietic agents for chemotherapy-induced anemia, traditional single time-point end points (e.g., hematopoietic response [HR]) fail to reflect clinical benefits over the entire therapy course. Area under the hemoglobin change curve (Hb AUC) is introduced as an alternative measure, and its reliability, clinical significance, and superiority are assessed.
INTRODUCTION
Cancer patients with chemotherapy-induced anemia (CIA) typically experience fatigue, shortness of breath, diminished functional status, and suboptimal quality of life (QOL) [1] . Fatigue, one of the most debilitating effects of cancer and its treatment [2] , can develop relatively quickly after the onset of chemotherapy [3, 4] ; it has been recognized that prompt and sustained relief of this symptom of anemia is an important goal of supportive treatment [5] [6] [7] [8] [9] [10] . There is little doubt that a relationship exists among hemoglobin (Hb) level, fatigue, and QOL, and that raising Hb levels can relieve the symptom of fatigue and improve QOL [2, 11, 12] . However, investigations of erythropoietic agents have only just begun to consider the clinical importance of prompt Hb improvement.
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In a recent retrospective analysis of data from two large, open-label clinical studies [13, 14] , Rosberg and colleagues [15] observed that clinical outcomes-including patient QOL, transfusion requirements, and average weekly doseimproved in patients who responded early to epoetin alfa (EPO; Procrit ® ; Ortho Biotech Products, L.P., Bridgewater, NJ, http://www.orthobiotech.com), by week 4, compared with late or nonresponders. In addition, patients with CIA receive erythropoietic therapies for relatively short periods [16] [17] [18] [19] and are sensitive to the time constraints imposed on their lives as a result of their cancer diagnosis. Glaspy et al. [9] recognized a front-loading dosing strategy as one that could potentially enhance the benefit of treatment with an erythropoietic agent, minimizing the time to achieve a hematopoietic response so as to avoid transfusion risks and gain symptom relief as quickly as possible. With these observations in mind, the rate of Hb response is an important consideration in caring for the patient with cancer, and it is a clinically relevant parameter with which to judge the effectiveness of an erythropoietic agent.
Existing studies of erythropoietic agents for CIA have been conducted with different patient populations and have used different methodologies, most frequently single time point-based and threshold-based end points of clinical efficacy [6, 7, 14, 20, [21] [22] [23] . These end points have included: A) Hb response, defined as an increase from baseline of ≥2 g/dl occurring at any time point in the study in the absence of transfusions, usually within the preceding 28 days; B) hematopoietic response (HR), defined as an Hb increase from baseline of ≥2 g/dl or an Hb level ≥12 g/dl occurring at any time point in the study in the absence of transfusions, usually within the preceding 28 days; C) mean change in Hb from baseline measured at specified time points, usually at monthly intervals; or D) RBC transfusion requirements over specified time intervals.
However, a study by Cremieux et al. [24] , comparing the cost-effectiveness of EPO with that of the standard-of-care in patients with CIA, supported the idea that cumulative Hb gains measured over the entire course of therapy may be a more useful measure, as cumulative gains did not mask differences in trends between the two interventions over the course of the study. In addition, if one accepts that early symptom relief is an important therapeutic goal, thresholdbased measurements such as HR provide little indication of the onset of patients' responses, and so insufficiently distinguish between agents or regimens that provide early benefit. Thus, the ideal method would reveal strong correlations between objective laboratory measures of efficacy (e.g., Hb change) and clinical benefits (e.g., reduced transfusion needs and improvements in QOL), and capture the concept of timeto-response. The area under the Hb change curve (Hb AUC) method is one such approach, in which the cumulative effects of erythropoietic agents can be assessed from the beginning to the end of therapy. An AUC measure enables clinicians to evaluate erythropoietic agents based on the benefits to patients over the entire course of therapy and improves the detection of early benefit, particularly if threshold-based responses are equivalent at the end of therapy. In fact, Egrie and colleagues [25] indicated that the AUC provided the most robust measure of biological activity of erythropoietic agents, as compared with mean Hb values at single time points or imposing linearity in log dose-response curves.
Pharmacokinetic studies have been the traditional avenue for the application of the principles associated with AUC measurements, in which AUC is defined as the total area under the curve describing drug concentration in the systemic circulation as a function of time [26] . In broad applications, studies have used AUC extensively to monitor, assess, and compare the effects of various therapeutic entities [27] [28] [29] [30] [31] . Regulatory agencies are also accepting of AUC methods. For example, a guidance issued by the Center for Drug Evaluation and Research (CDER) directing the clinical evaluation of analgesic drugs suggested that the cumulative effect, as well as peak effects and time-to-peak effects, of such drugs could be assessed using the AUC [32] . Other examples exist in the literature that confirm the utility of AUC methods in evaluating the clinical effectiveness of drugs and biologics [33] [34] [35] [36] .
With specific regard to erythropoietic agents, studies have used AUC as a metric for evaluating equivalence [37] , hematologic benefits [38] , and dose conversion ratios [39] , among other variables [40, 41] . Illustrated with Hb change data following treatment with erythropoietic agents, this manuscript introduces the concepts and rationale for the use of Hb AUC as an efficacy measure. Additionally, it is herein shown that the Hb AUC can also be used to facilitate an appropriate comparison of erythropoietic agents. However, readers should bear in mind that Hb-based end points, whether the continuous Hb AUC or the discrete HR, need to be interpreted with caution due to other confounding host factors (e.g., nutritional deficiencies [42, 43] , patient or tumor characteristics [42, [44] [45] [46] , depression or other psychiatric diagnoses [42, 46, 47] , insomnia [42, 43, 48] , and infections [42, 43] ) that may correlate with the multifactorial causes of CIA or its associated fatigue.
The objectives of this study were fourfold: A) to demonstrate how the Hb AUC can be calculated; B) to demonstrate that the Hb AUC can be reliably calculated using either published aggregated or primary patient-level data; C) to demonstrate that the Hb AUC correlates with accepted measures of clinical benefit; and D) to demonstrate that the Hb AUC, as a comprehensive continuous variable, is more informative than a discrete single time-point measure.
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METHODS

Calculating the Hb AUC
The trapezoidal rule is the simplest and most common approach used to calculate AUC [49] , in which the total area under the Hb change versus time curve is obtained by summation of each individual area between two consecutive time intervals. This AUC value approximates the integral of Hb change values over time obtained from values of the ordinate and the abscissa [50] . The slope, or the first derivative of the Hb AUC curve, represents the rate of rise of Hb. Figure 1 illustrates the Hb AUC calculation using the trapezoidal rule by aggregating data from a phase IV, multicenter, open-label study [14] , in which 2,964 patients received EPO once weekly (QW) at a dose of 40,000 units over the course of 16 weeks. Dose escalations to 60,000 units QW were made if, at study week 4, the patient's Hb level had not increased by at least 1 g/dl over baseline. We calculated the 16-week Hb AUC value as follows:
1. We constructed the curve by plotting the mean change in Hb from baseline at each time point and drawing straight lines to connect the time points. In plotting these data, Hb measurements recorded within 28 days of an RBC transfusion were considered missing to avoid attributing the Hb effect of transfusions to that of EPO therapy.
2. We divided the entire area under the curve into rectangles and triangles of measurable dimensions (A through G), as shown in Figure 1 .
3. We calculated each area by using simple geometric formulas, and summed as follows:
iii. Area of each rectangle (C, E, G) = base × height iii. Summation of areas A through G = Hb AUC
In the aforementioned study [14] , the calculated Hb AUC was 24.0 g/dl, based on monthly average Hb changes, independent of blood transfusion, observed over the 16-week course of treatment in 2,627 on-treatment patients who had no RBC transfusions within 28 days prior to baseline.
The accuracy of the trapezoidal method in calculating the Hb AUC hinges on the number of time points available; the more time points, the more accurate the measure.
However, if the time points are spaced widely, meaning that there are few of them, the imprecise curvature of the line will cause a greater error in the area estimate [49] .
In addition to this example, we presented the Hb AUC values using the trapezoidal rule based on aggregated-level data from other published studies of EPO [6, 7, 13, 51] and darbepoetin alfa (DARB; Aranesp ® ; Amgen Inc., Thousand Oaks, CA, http://www.amgen.com) [52, 53] as well.
The Reliability of the Hb AUC
We determined the reliability of the Hb AUC using data from the aforementioned study [14] , by comparing the Hb AUC values derived from patient-level data with those derived from aggregated-level data using two statistical approaches for the treatment of missing Hb values. In the first analysis, we used an on-treatment approach without imputing any missing Hb values. In the second analysis, we used the last-value-carry-forward (LVCF) principle to impute missing Hb measurements. For the purpose of calculating the Hb AUC, all Hb measurements recorded within 28 days of an RBC transfusion were considered missing. For aggregated-level data, we determined Hb AUC values using aggregated mean changes in Hb over baseline at weeks 4, 8, 12, and 16. For patient-level data, we calculated , missing values were not imputed), where Hb measurements recorded within 28 days of an RBC transfusion were considered missing (337 patients who had RBC transfusions within 28 days of baseline were excluded). In this illustration, the Hb AUC was 24.0 g/dl over 16 weeks, computed from Σ (areas A + … + G), where:
the Hb AUC for each patient and summarized the mean Hb AUC across all patients.
To determine how the frequency of Hb values could affect Hb AUC, we used three samples of patients that had different frequencies of Hb measurements during the study. First, we analyzed all patients eligible for the study (n = 2,964). Second, we calculated the Hb AUC for the subset of patients that had nonmissing Hb values at the study end (n = 1,622). Finally, we examined patients with nonmissing Hb measurements for all visits (i.e., baseline and weeks 4, 8, 12, and 16; n = 1,266).
The Clinical Significance of the Hb AUC
We investigated the clinical significance of the Hb AUC by examining the correlations between the Hb AUC and several established measures of clinical benefit. The clinical parameters with which the Hb AUC were benchmarked included RBC transfusion rates, patient-reported QOL, and time to achieve an HR. Patient QOL was evaluated based on the overall Linear Analogue Scale Assessment (LASA) and the Functional Assessment of Cancer Treatment subscales for the anemia (FACT-An) and fatigue (FACT-F) parameters.
We used data from multiple EPO studies to ensure the replicability of the findings. Individual patient data from three phase IV, multicenter, single-arm, open-label, 16-week EPO trials were used; two used an initial EPO dose of 40,000 units QW [13, 14] , and one used an initial dose of 10,000 units thrice weekly (TIW) [7] . For each patient, we calculated the Hb AUC by using the trapezoidal method that accumulated the Hb AUC from baseline to week 16 of the EPO therapy, with Hb values recorded within 28 days of an RBC transfusion considered missing. We used the LVCF principle to impute missing Hb values, and the Hb AUC was formulated as a categorical variable based on quartile distribution (0-25th, 26th-50th, 51st-75th, and 76th-100th percentiles).
For binary outcomes (i.e., RBC transfusion rate), the Cochron-Armitage trend test was used to determine whether there was a significant decreasing linear trend of percentages of patients transfused across Hb AUC quartiles. For continuous variables (i.e., QOL change scores, time to HR), the t-statistic was used to test whether there was a significant increasing/decreasing linear trend of the means of the outcome across Hb AUC quartiles.
Potential Advantages of Hb AUC Methodology Over Traditional Discrete Time-Point Hb Measures
To demonstrate that Hb AUC is a more informative measure than HR, we compared Hb AUC with HR in the degree of association with the blood transfusion rate, using patientlevel data from an aforementioned study that used an initial EPO dose of 40,000 units QW (n = 2,964) [14] .
Two different analyses were undertaken. First, the dependent variable of interest, the RBC transfusion rate, a binary variable indicating whether a patient received RBCs during the 16-week trial, was logistically regressed on both the continuous Hb AUC and the binary HR variables, along with other covariates for adjustment (i.e., age, gender, baseline Eastern Cooperative Oncology Group [ECOG] performance status score, baseline FACT-An score, primary site of malignancy, chemotherapeutic agent, and radiation therapy dummy). The simultaneous presence of the Hb AUC and the HR variables in the model allowed the two variables to compete with each other to explain the transfusion outcome. That is, the variable that was stronger in the association with blood transfusion would retain its statistical significance, while the other would be rendered insignificant.
In the second analysis, we conducted two separate logistic regression models for the RBC transfusion outcome. Thus, while the same adjusting covariates as defined above were included for both models, one model included the Hb AUC while the other included the HR as an independent variable. We then determined the accuracy of the Hb AUCbased versus the HR-based model in predicting RBC transfusion using the area under the receiver operating characteristic (ROC) curve [54] . We constructed ROC curves by computing the sensitivities and specificities of the Hb AUC-based and HR-based models in predicting RBC transfusion rate. The area under the ROC curve is a measure of the probability that the model (Hb AUC-based or HRbased) will correctly classify whether a patient received a blood transfusion. ROC curves show the discriminatory ability of a model by the position of the curve; the farther upward and to the left the curve lies in the graph, the greater the area, and the better the performance of the model. Figure 2 shows that a perfect model has an area under the ROC curve equal to one; a classification model with no predictive power, as it is equal to randomly assigning patients to receiving blood transfusion, has an area under the curve equal to 0.5, and is described by the 45-degree identity line. Swets suggested that areas of 0.5 to <0.7 reflect low accuracy, 0.7 to <0.9 reflect moderate accuracy, and 0.9 or above reflect high accuracy [55] . The areas under the ROC curves from the two models were compared using the nonparametric Mann-Whitney statistic [56] .
RESULTS
Calculating the Hb AUC
The Hb AUC values calculated from available published studies of EPO and DARB are presented in Table 1 . The front-loading dosing regimens of DARB reached a similar early Hb improvement at week 4 to those in the EPO studies,
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Assessing Erythropoietic Benefit Using Hb AUC resulting in similar Hb AUC values. In contrast, the DARB Q2W study had a lower week 4 Hb change than the other studies, leading to a lower Hb AUC. This suggests that the Hb AUC is more sensitive than the end of study Hb measurement in detecting early Hb response and reflects the comprehensive Hb effect over the entire course of treatment. Table 2 presents the comparison of aggregated-level versus patient-level Hb AUC values from a previously mentioned phase IV, multicentered, open-label study [14] for three samples of patients with different frequencies of Hb measurements (i.e., all patients, patients with nonmissing Hb measurement at study end [completers] , and patients with nonmissing Hb measurements for all visits). In addition, we show the data across the two different statistical approaches in treating missing Hb values-on-treatment refers to the approach in which missing measurements were not imputed, while LVCF refers to the approach in which the LVCF principle was used to impute the missing values.
The Reliability of the Hb AUC
Aggregated-level and patient-level Hb AUC values were mathematically identical when missing Hb readings were imputed using the LVCF method. Moreover, on-treatment Hb AUC values calculated from aggregated-level data were systematically equal to or higher than LVCF Hb AUC values, indicating that the LVCF principle is a conservative approach.
Comparisons of the Hb AUC values across the three different samples showed that the Hb AUC value tended to be higher when more Hb points were available, while the variability of Hb AUC values was smaller when on-treatment data were used compared with LVCF data.
This information suggests that, when LVCF data are used, the Hb AUC can be reliably derived using published data, as its value is identical to that using primary patient data. If published data report Hb changes for on-treatment Example of receiver operating characteristic (ROC) graph. The "perfect," "worthless," and "intermediate" classification models are depicted. A "perfect" model correctly predicts the outcome status for every subject, resulting in the area under the ROC curve equal to 1. A "worthless" model is analogous to tossing a coin in predicting the outcome status for each subject, resulting in an area under the ROC curve equal to 0.5. The "intermediate" classification model falls between the "perfect" and "worthless" models. Abbreviations: Hb AUC = area under the hemoglobin change curve; Hb = hemoglobin; EPO = epoetin alfa; DARB = darbepoetin alfa; QW = once weekly; Q2W = once every 2 weeks; Q3W = once every 3 weeks; TIW = thrice weekly. patients, the estimated Hb AUC value would tend to be higher than that based on a LVCF approach.
The Clinical Significance of the Hb AUC
The relationships between the Hb AUC quartiles and the RBC transfusion rate, patient-reported QOL, and time to achieve HR across the three EPO studies [7, 13, 14] are shown in Figure 3A -3E, respectively.
Consistently observed across all three EPO trials, increasing Hb AUC values were well-correlated with statistically significantly improved clinical outcomes, including a decreasing linear trend of transfusion (p < .0001), an increasing linear trend of QOL improvement (p < .0001), and a decreasing linear trend of time to HR (p < .0001). Table 3 presents the results from the logistic regression model that permitted Hb AUC and HR to compete simultaneously to explain the risk of RBC transfusion during the study. The regression resulted in an insignificant coefficient on HR (p = .5181), but a significant coefficient on Hb AUC (p < .0001). Thus, the model revealed that the Hb AUC variable could explain the risk of transfusion with statistical significance even in the presence of an HR variable. In contrast, when controlling for Hb AUC, the binary HR variable failed to explain the risk of RBC transfusion with statistical significance. These results indicate that the association between Hb AUC and RBC transfusion is stronger than the corresponding association between HR and RBC transfusion.
Potential Advantages of Hb AUC Methodology Over Traditional Discrete Time-Point Hb Measures
In a further confirmatory analysis, ROC curves derived from Hb AUC-based and HR-based logistic regressions were compared (Fig. 4) . The area under the ROC curve for the Hb AUC-based model was 0.74, compared with 0.69 for the HR-based model. These two areas were found to be statistically significantly different (p < .0001), indicating that the Hb AUC-based model was more accurate in predicting RBC transfusion than the HR-based model.
DISCUSSION
In this retrospective study using data from multiple phase IV EPO trials, we have demonstrated that the Hb AUC is an objective, comprehensive, reliable, and clinically meaningful alternative measure for hematological efficacy of erythropoietic agents. We found that the Hb AUC reflected early Hb response as well as the comprehensive Hb effect from the entire course of the erythropoietic therapy better than the end of study Hb measurement. The Hb AUC can be reliably approximated using either published or primary data. Its validity as a laboratory Hb end point is supported by its strong correlation with clinical end points (i.e., RBC transfusion rate, patient-reported QOL, and time to achieve HR). Moreover, the Hb AUC is potentially more advantageous than the traditional discrete single time-point measure of HR, as it provides more information as a continuous variable. We showed that when the Hb AUC and HR variables were present in a regression model simultaneously, the Hb AUC overwhelmed the HR in explaining the probability of an RBC transfusion. Furthermore, when the Hb AUC and HR were separately inserted into a regression model, the model with the Hb AUC, all else equal, outperformed the model with the HR in the degree of association with RBC transfusion.
The AUC methodology that we introduced in this paper can be further developed and refined in its application to the assessment of erythropoietic agents through selecting the optimal number of time points and replicates per time point Abbreviations: Hb AUC = area under the hemoglobin change curve; Hb = hemoglobin; LVCF = last-value-carry-forward.
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Assessing Erythropoietic Benefit Using Hb AUC to obtain the most accurate and precise estimate of the Hb AUC [57] , as well as through penalizing overly high Hb readings that may be associated with safety concerns in the construction of the Hb AUC. In addition, corrected Hb AUC, defined as the total Hb AUC per unit of time, can be used to adjust for different observation durations when comparing across studies of different lengths. Furthermore, methods for Hb AUC calculation in an observational study setting, in which the extent of missing values in Hb data is usually greater than that in a clinical trial setting, need to be enhanced as well. When comparing EPO with DARB from available published aggregated data, the Hb AUC of EPO was higher than that of DARB. As shown in Table 1 , the Hb AUC of DARB approached the Hb AUC of EPO studies only when front-loading dosing strategies of DARB were used. However, it is important to note that the studies compared in Table 1 were conducted at different times, with populations that had different baseline characteristics, tumor types, and treatment regimens, for which adjustments were not made.
The Hb AUC measure introduced herein needs to be further validated in a prospective randomized trial that compares EPO and DARB users arising from the same source population. However, to the extent that it is valid to compare Hb AUC results across different studies, inspection of representative curves that illustrate Hb effect over time is instructive and demonstrates a worthwhile concept to be incorporated into future study designs.
CONCLUSION
The Hb AUC measure is an objective, reliable, valid, and comprehensive summary statistic that may be used to quantify clinical benefits for patients receiving erythropoietic In three studies in which EPO was administered either at a starting dose of 40,000 units once weekly (study 1 [14] and study 3 [13] ) or 10,000 units thrice weekly (study 2 [7] ), the observed linear trends of decreasing transfusion rate (A), increasing patient QOL (B-D), and decreasing time to hematopoietic response (E) with increasing Hb AUC quartile were statistically significant (p < .0001, p < .0001, p < .0001, respectively). LASA scores ranged from 0-100 (mm). FACT-An and FACT-F scores have a maximum of 80 and 52 points, respectively. Data were not available from study 3 to calculate FACT-An and FACT-F scores. Abbreviations: Hb AUC = area under the hemoglobin change curve; LASA = Linear Analogue Scale Assessment; FACT = Functional Assessment of Cancer Therapy (-An = Anemia; -F = Fatigue); EPO = epoetin alfa.
agents. Higher Hb AUC values correlate well with other measures of erythropoietic efficacy, such as lower transfusion requirements, improved patient QOL, and faster time to HR. Hb AUC has also preliminarily been found to be superior to the traditional HR measure in its association with the RBC transfusion clinical end point. The Hb AUC metric may be considered in future studies as an alternative end point with which to assess the overall efficacy of erythropoietic agents. Hb AUC measurements may provide a means to compare the efficacies of erythropoietic agents throughout the entire Abbreviations: Hb AUC = area under the hemoglobin change curve; HR = hematopoietic response; ECOG = Eastern Cooperative Oncology Group; FACT-An = Functional Assessment of Cancer Treatment subscale for Anemia; CLL = chronic lymphocytic leukemia. . ROC curve analysis: comparison of the Hb AUC-based versus HR-based models in predicting the probability of RBC transfusion. The ROC curves for the Hb AUC-based and HR-based models are pictured, along with an ROC curve from a hypothetical "worthless" model that discriminates the probability of blood transfusion by chance alone (described by the 45-degree identity line). The greater the area under the ROC curve, the more accurate a model is in predicting the probability of RBC transfusion. More details on the interpretation of the ROC curves are presented in Methods and in Figure 2 . Abbreviations: Hb AUC = area under the hemoglobin change curve; Hb = hemoglobin; HR = hematopoietic response.
course of therapy. Being a more comprehensive reflection of erythropoietic efficacy than any single time point-based or threshold-based measure, the Hb AUC is expected to augment clinicians' informed decision making when choosing a therapy most likely to improve their patients' well-being.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
